08:54 AM EST, 01/22/2026 (MT Newswires) -- Corcept Therapeutics ( CORT ) said Thursday its phase 3 trial of relacorilant in combination with nab-paclitaxel met the primary endpoint of overall survival in patients with platinum-resistant ovarian cancer.

Patients treated with relacorilant in combination with nab-paclitaxel had a 35% reduction in the risk of death compared with nab-paclitaxel alone, with a median overall survival of 16 months versus 11.9 months, the company said.

The trial also met its dual primary endpoint of progression-free survival, with a 30% reduction in the risk of disease progression versus chemotherapy alone, Corcept Therapeutics ( CORT ) said.

Relacorilant in combination with nab-paclitaxel was well-tolerated and consistent with its known safety profile, the company said.

Shares of Corcept Therapeutics ( CORT ) were up over 20% in recent Thursday premarket activity.